Nanion Technologies GmbH ()

Nanion is an SME focussed on the automation and upscaling of electrophysiological recording techniques, with our core competence being high-throughput patch clamp electrophysiology. We develop medium to high throughput recording devices and their application for a broad range of research areas, drug discovery and safety screening.

Role and Commitment of key persons (including supervisors)

Dr. Niels Fertig, CEO, 5 %, Dr. Andrea Brüggemann, CSO, 5 %, Dr. Nadine Becker, Senior Scientist, 45 %, Dr. Markus Rapedius, Senior Scientist, 45 %.

Key Research Facilities, Infrastructure and Equipment

Nanion has fully equipped cell-culture and wet-lab facilities run by highly experienced staff. We have three large laboratories where we can run >15 of our instruments in parallel. Our scientific team consists of >20 PhD-level electrophysiologists covering a broad range of scientific backgrounds, collaborating with a team of >20 electrical and software engineers for technological and application development. We routinely supervise about 3-5 Bachelor, Master and PhD students.

Status of Research Premises

Nanion is a fully private SME, with all its facilities placed in a rented building with a long-term contract. Our research premises are fully independent.

Previous Involvement in Research and Training Programmes

EU: ITN IonTraC, IMI, ITN Translocation, CardioPredict, TransBio, OPTEL national: Nanopore Chip, Int2Screen, BFS i3 Screen, SyntHTEphys

Current Involvement in Research and Training Programmes

EU: ITN RELEVANCE, ITN Orgbio national: Sysmem2016, FLEXcyte

Relevant Publications and/ or Research/ Innovation Product

Rotordam, G.M., Fermo, E., Becker, N., Barcellini, W., Brüggemann, A., Fertig, N., Egée, S., Markus Rapedius, M., Bianchi, P., Kaestner, L. (2018) A novel gain-of-function mutation of Piezo1 is functionally affirmed in red blood cells by high-throughput patch clamp. Haematologica, doi: 10.3324/haematol.2018.201160